Synthesis and evaluation of a tri-tyrosine decorated dextran MR contrast agent for vulnerable plaque detection.

This communication reports the synthesis, characterization and in vivo evaluation in mice of a new tri-tyrosine conjugated MR contrast agent, which may help to identify vulnerable plaques in atherosclerosis by targeting the lipid core.

[1]  D Revel,et al.  Kinetic characterization of CMD‐A2‐Gd‐DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI , 2000, Magnetic resonance in medicine.

[2]  S. Kaul,et al.  Differential Effects of Apolipoprotein A-I–Mimetic Peptide on Evolving and Established Atherosclerosis in Apolipoprotein E-Null Mice , 2004, Circulation.

[3]  C. Corot,et al.  Physical, chemical and biological evaluations of CMD-A2-Gd-DOTA. A new paramagnetic dextran polymer. , 1997, Acta radiologica. Supplementum.

[4]  Emmanuelle Canet-Soulas,et al.  A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. , 2007, Contrast media & molecular imaging.

[5]  R. J. Dimler,et al.  Interpretation of Periodate Oxidation Data on Degraded Dextran , 1955 .

[6]  Gerrit L ten Kate,et al.  Noninvasive imaging of the vulnerable atherosclerotic plaque. , 2010, Current problems in cardiology.

[7]  R. Epand,et al.  Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. , 2001, Journal of lipid research.

[8]  S. Reddy,et al.  Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides Published, JLR Papers in Press, June 14, 2007. , 2007, Journal of Lipid Research.

[9]  Y. Marcel,et al.  Apolipoprotein A-I: structure-function relationships. , 2000, Journal of lipid research.

[10]  Hiroyuki Saito,et al.  Surface plasmon resonance analysis of the mechanism of binding of apoA-I to high density lipoprotein particles , 2010, Journal of Lipid Research.

[11]  Zahi A Fayad,et al.  Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography , 2007, Nature Medicine.

[12]  G. Getz,et al.  An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide , 2009, Journal of Lipid Research.

[13]  A. Sulaiman,et al.  Contrast enhancement in atherosclerosis development in a mouse model: in vivo results at 2 Tesla , 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.

[14]  M. Navab,et al.  Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. , 2008, Clinical immunology.

[15]  R. Epand,et al.  Aromatic Residue Position on the Nonpolar Face of Class A Amphipathic Helical Peptides Determines Biological Activity* , 2004, Journal of Biological Chemistry.

[16]  A. Waring,et al.  Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I , 2008 .

[17]  S. Reddy,et al.  Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal , 2004, Current opinion in lipidology.